Sinigrin (Glucosinolate)

Sinigrin is a glucosinolate compound found primarily in cruciferous vegetables that demonstrates anti-inflammatory and anti-cancer properties through p53 tumor suppressor activation. This bioactive compound modulates cytokine production and cellular apoptosis pathways in preliminary research.

Origin & History

Sinigrin is a sulfur-containing glucosinolate found primarily in Brassica plants including black mustard (Brassica nigra), white mustard (Sinapis alba), and cruciferous vegetables like watercress and broccoli. It originates in plant vacuoles, particularly in protein bodies of seeds and seedlings, and is extracted through solvent extraction followed by purification. Upon plant tissue damage, sinigrin is hydrolyzed by myrosinase enzyme to form allyl isothiocyanate (AITC), its primary bioactive metabolite.

Historical & Cultural Context

While isolated sinigrin lacks documented traditional use, it occurs naturally in mustard plants historically used in European folk medicine for antimicrobial and anti-inflammatory purposes. However, traditional benefits are attributed to glucosinolate breakdown products rather than sinigrin itself.

Health Benefits

• Cardiac protection: Reduced inflammation and fibrosis in rat models at 7.5-30 mg/kg doses, lowering IL-1β, TNF-α, and IL-6 markers (preliminary animal evidence)
• Anti-cancer activity: Inhibited liver and colon tumor formation in rats through p53 upregulation and Bcl-2 downregulation (preliminary animal evidence)
• Anti-inflammatory effects: Blocked JNK/p38 MAPK phosphorylation and suppressed NLRP3 expression in preclinical models (preliminary in vitro evidence)
• Cytotoxic to cancer cells: Showed 46% inhibition of cancer cells with minimal toxicity to normal cells, enhanced to 74% in phytosome form (preliminary in vitro evidence)
• Metabolic effects: Altered lipid profiles including cholesterol and triglycerides in 14-day rat studies (preliminary animal evidence)

How It Works

Sinigrin exerts its effects by upregulating the p53 tumor suppressor protein while simultaneously downregulating the anti-apoptotic protein Bcl-2, promoting programmed cell death in cancer cells. The compound also modulates inflammatory pathways by reducing pro-inflammatory cytokines including interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These mechanisms contribute to both its cardioprotective and anti-cancer activities through reduced inflammation and enhanced cellular quality control.

Scientific Research

No human clinical trials, RCTs, or meta-analyses on isolated sinigrin were identified. A review of 126 registered glucosinolate trials over 20 years found none using sinigrin as the sole intervention. Current evidence is limited to preclinical animal studies including cardiac protection in rats (PMID: 41005146) and in vitro cancer cell studies.

Clinical Summary

Current evidence for sinigrin is limited to preliminary animal studies in rat models. Cardiac protection studies demonstrated reduced inflammation and fibrosis at doses of 7.5-30 mg/kg, with significant decreases in inflammatory markers IL-1β, TNF-α, and IL-6. Anti-cancer research showed inhibition of liver and colon tumor formation through p53 upregulation and Bcl-2 downregulation mechanisms. Human clinical trials are not yet available to confirm these preliminary findings or establish safe and effective dosing protocols.

Nutritional Profile

Sinigrin is a glucosinolate compound (molecular formula C10H19NO9S2, MW 359.39 g/mol) found predominantly in Brassica vegetables. It is not a macronutrient or micronutrient itself but a bioactive secondary metabolite. Typical concentrations in plant sources: Brussels sprouts (2.0–7.0 mg/g dry weight), black mustard seeds (Brassica nigra, 50–150 mg/g dry weight, one of the richest sources), horseradish (1.0–10.0 mg/g dry weight), cabbage (0.5–2.5 mg/g dry weight), and broccoli (trace to 0.5 mg/g dry weight). Sinigrin is a β-thioglucoside consisting of a glucose moiety linked to an allyl glucosinolate side chain with a sulfate group. Upon hydrolysis by myrosinase (released during plant tissue damage or gut microbial activity), sinigrin converts to its bioactive breakdown products: allyl isothiocyanate (AITC, also known as mustard oil), allyl cyanide, and allyl thiocyanate — these hydrolysis products are the primary drivers of observed biological activity. Bioavailability: Sinigrin itself is water-soluble and absorbed in the small intestine, though gut microbiota-mediated conversion in the colon also contributes to systemic exposure. Cooking significantly reduces sinigrin content (boiling can degrade 30–60% depending on duration and temperature). Myrosinase is heat-labile, reducing hydrolysis to AITC in cooked preparations, though colonic bacteria partially compensate. No caloric contribution is significant at physiological doses. Contains sulfur as a structural component (~8.9% by molecular weight). No direct vitamin, mineral, or fiber content is attributed to sinigrin as an isolated compound.

Preparation & Dosage

No clinically studied human dosages exist. Animal studies used oral doses of 7.5-30 mg/kg for cardiac effects and 1000 ppm in diet for cancer prevention models. Human dosing cannot be extrapolated from these animal studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Sulforaphane, Indole-3-carbinol, Quercetin, Curcumin, Green tea extract

Safety & Interactions

Safety data for sinigrin supplementation in humans is currently lacking, as research has been limited to animal models. Potential interactions with cancer medications targeting p53 pathways or anti-inflammatory drugs should be considered due to sinigrin's effects on these systems. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data. Individuals with existing liver or colon conditions should consult healthcare providers before use given the compound's effects on these tissues in animal studies.